Hu et al. showed that depletion of the deubiqitinase enzyme (DUB), OTUD7B, enhanced signaling in dendritic cells.32 DUB inhibitors have been developed for cancer therapy.71 While none have been developed specifically for OTUD7B, existing chemoproteomic methods could indicate whether any existing inhibitors have significant off target affinity on OTUD7B.72 There are only roughly 100 DUBs, so as more inhibitors are developed, an important goal is to characterize their biochemical affinities across the spectrum of DUBs. The gene discussed is ZUP1; the disease is cancer.